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COPDAbstract Objective: To assess cough peak ﬂow in patients with frequent infective exacerbations of
COPD.
Design: Cross-sectional controlled clinical study.
Settings: Pulmonary function laboratory of the Chest Department of Ain Shams University Hos-
pitals, Cairo, Egypt.
Patients: Forty male patients with severe COPD; twenty with stable disease and twenty with more
than two exacerbations in the last year were included in the study.
Interventions: Spirometry and cough peak ﬂows were measured at least six weeks after recovery
from their last exacerbation.
Results: Both groups were matched as regards demographics and lung functions. There was a sta-
tistically signiﬁcant lower CPF in the frequent exacerbation group.
Conclusion: Cough peak ﬂow can guide respiratory physicians in ﬁne tuning the management of
patients with severe COPD to their particular needs.
ª 2014 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
Open access under CC BY-NC-ND license.Introduction
COPD patients have generalized muscle weakness caused by
deconditioning, malnutrition, electrolyte disturbances, cardiac
failure, systemic inﬂammation and treatment with corticoste-
roids causing steroid-induced myopathy [1].
Inspiratory muscle weakness is more pronounced than
the expiratory muscle weakness in patients with COPD [2].This is thought to be caused by hyperinﬂation placing the
inspiratory muscles at a mechanical disadvantage, while sev-
eral studies reported that impaired expiratory muscle
strength in most patients with signiﬁcant COPD is thought
to be part of the generalized muscle weakness in these
patients [3–6].
In patients with neuromuscular diseases the inefﬁcient
cough secondary to affection of expiratory muscles is thought
to be responsible for bronchial mucus retention, atelectasis and
infection which have deleterious effects on their condition.
Cough peak ﬂow (CPF) is an acceptable alternative to measur-
ing maximal expiratory ﬂow (MEP) in assessing expiratory
muscle weakness in these patients especially as performing
the MEP can be quite cumbersome [7].
838 S. El Batrawy, G. ElassalThere is a move toward phenotyping patients with COPD
and hence optimizing and tailoring therapeutic interventions
to their needs. A phenotype that we commonly see is the
frequent exacerbators. With the strain on resources in Egypt
there is always the need to ﬁnd cheap easy to use instruments
and measures that can help physicians provide good quality
care to patients. Cough peak ﬂow has this potential.
Aim of the work
To assess cough peak ﬂows as a measure of respiratory muscle
weakness in patients with severe COPD who have frequent
exacerbations.Table 1 The mean and standard deviation of demographic,
arterial blood gas, and CPF values of groups A and B as well as
P value on doing unpaired t test with Welch correction when P
less than 0.05 were considered statistically signiﬁcant.
Group B Group A P value
Mean SD Mean SD
Age 60.4 3.7 61.8 4.3 0.05
BMI 29.6 2.4 28.3 2.2 0.06
Sm.Index# 43.4 14.7 50.8 19.6 0.2
PH 7.39 0.04 7.4 0.04 0.16
PCO2 42.3 10.2 48 14 0.15
PO2 85 5.7 72 8.2 0.0001
Sat 87 8 88 7 0.6
CPF 179 19.7 164 24.8 0.04Subjects and methods
Forty male patients with severe COPD patients were enrolled
in this study. The diagnosis and severity of the condition were
established by history taking, thorough clinical examination
and spirometry according to the American Thoracic Society
criteria.
They were grouped into two subsets.
Group 1: Twenty patients with stable disease with less than
2 exacerbations in the last year.
Group 2: Twenty matched COPD patients with more than 2
exacerbations in the last year.
Routine blood tests, spirometry and cough peak ﬂows were
measured at least six weeks after recovery from their last
exacerbation.
All patients were on optimal medications for their condi-
tion. None of the patients were on long term oxygen therapy
or steroids. Some had co morbidities but they were all con-
trolled and none had any other system failure.
Each subject was instructed by a single, non blinded techni-
cian, to reduce inter observer variability.
Patients performed standard spirometric tests using a Yaeger
Viasys spirometer meeting the American Thoracic Society
recommendations for accuracy and precision. Subjects were
asked to blow as forcibly as they could into the mouthpiece
from a full inspiration. Three measures were carried out and
we considered the best of three to represent each individual.
CPF was measured using the Mini–Wright Peak Flow
Meter from Clement Clarke International Ltd., portable, made
of plastic material. It was used in order to assess the strength
and speed exerted by the expiration in liters per minute
(L/min). During the period in which we used our mechanical
tool we did not realize any damage of the instrument. The
testing was done in sitting position in a chair with no armrest.
Subjects were seated and asked to perform a voluntary cough.
The volunteers performed a maximal inspiration, followed by
a quick, short and explosive expiration on the peak ﬂow meter.
The difference from the peak expiratory ﬂow is the higher
glottis pressure and the higher resistance induced by the closed
glottis, which characterizes a forced cough. Three measures
were carried out and we considered the average of three results
for each individual.
The study obtained ethical approval from the Chest
Department, Ain Shams University. The study and procedures
were explained to the patients and appropriate consent was
obtained.Data were analyzed using graphpad prism 6 for windows
version 6.04 (trial) – graphpad software Inc. – statistical
package and compared with unpaired t test with the Welch
correction and P of less than 0.05 was considered statistically
signiﬁcant.
Results
Forty male patients with severe COPD FEV1 <30% were
enrolled in this study.
Group 1: Twenty patients with stable COPD having had
less than 2 exacerbations in the last year.
Group 2: Twenty patients with more than 2 exacerbations in
the last year.
The mean and standard deviation of demographic, arterial
blood gases and CPF values are summarized in Table 1 and
comparisons are illustrated in Figs. 1–3.
Discussion
The clinical relevance of the CPF has been deﬁned primarily in
patients with neuromuscular ventilatory impairment and those
that need weaning from endotracheal to tracheostomy tubes.
In the absence of bronchial obstruction, the peak ﬂow (PF)
evaluates the dynamic performance of the expiratory muscles
and monitoring PF–CPF difference is useful to monitor expi-
ratory muscle weakness and bulbar involvement and to assess
its evolution in these patients [7].
The ﬁrst publication that considered CPF in normal sub-
jects was published by Leiner et al. [8]. In healthy individuals,
the average CPF is higher than 300 L/min in Caucasian Euro-
pean subjects. Additionally, it must be higher than 160 L/min
for an effective cough [9]. There is an increasing rate of change
of cough ﬂow during a cough sequence when children get
older. Notably, the minimum CPF accepted as normal for
the adult population (400 L/min) is shown to be reached in
the pediatric subjects between ages 12 and 13 in both males
and females [10]. More recently normal values for Brazilian
healthy adults ranged between 240 and 500 L/min [11]. There
are no normative values for Egyptians but this applies to all
spirometric and lung function values.
The expiratory muscles have an important function in
clearing the airways by producing ‘effective’ cough. The con-






































Figure 1 Comparison between groups A and B as regards age, smoking index and body mass index (BMI). There was no signiﬁcant



























































Figure 2 Comparison between groups A and B as regards PH, PO2, PCO2, and O2 saturations. Group B had signiﬁcantly worse PO2
values compared to group A.
Cough peak ﬂow in assessment of patients with severe COPD 839pressure, diminishes lung volume, and facilitates expiratory
ﬂow in the absence of ﬂow limitation. For cough to be
effective, the ﬂow generated by the expiratory muscles should
be high .This may be compromised by diseases of the
lung parenchyma, weak respiratory muscles and laryngeal
dysfunction [12].
PEFR cannot be considered as a surrogate measure of
cough efﬁciency. PEFR measures expiratory ﬂow through an
open glottis, whereas the forceful expiratory ﬂow of a normal
cough follows a glottic closure of about 0.2 s. As a conse-
quence, CPF measurements directly assess bulbar-innervatedmuscle function. PEFR can be measurable in the absence of
CPF, when the glottis cannot be closed [13].
The CPF correlates with respiratory muscle strength, espe-
cially with inspiratory muscle strength. In the inspiratory
phase of cough, inhalation of high volumes promotes a
relationship between time and tension of the muscles and
increases the elastic recoil of the respiratory system, optimizing
expiratory pressures. The muscle strength to inhale appropri-
ate volumes leading to chest expansion and the muscle force
to increase intrathoracic pressure are important to generate












Figure 3 Comparison between groups A and B as regards cough
peak ﬂow (CPF). Group B had statistically signiﬁcant lower CPF
than group A.
840 S. El Batrawy, G. ElassalIn this study both groups comparably had severe COPD
with no statistically signiﬁcant difference as regards their
demographics. The arterial blood gas value of group B was sig-
niﬁcantly worse which reﬂects the disease burden on this group
and its impact on morbidity. The group which had more chest
infections had a statistically signiﬁcant lower cough peak ﬂow.
Respiratory and peripheral muscle dysfunctions have
signiﬁcant consequences for COPD patients. They are associ-
ated with reduced exercise tolerance and reduced quality of
life. Both are independent determinants of survival, in addition
to the degree of airﬂow obstruction as measured by FEV1.
Also the utilization of health care resources appeared to be
related to respiratory and peripheral muscle weakness. Treat-
ment of respiratory and peripheral muscle weakness in COPD
patients is possible. Respiratory and peripheral muscle training
has been shown to produce beneﬁcial effects especially if they
are used in combination with nutritional interventions and
anabolic steroids [1].
There is a paucity of data related to the expiratory muscles
(abdominal muscles and the internal intercostal muscles) in
patients with COPD. These muscles have been found to be
recruited in such patients both at rest and during loaded
breathing. The signiﬁcance of this activation has not been well
deﬁned; however, it is considered to be a mechanism that
provides the system with functional reserve. Expiratory muscle
strength and endurance can be impaired in patients with
COPD and therefore decrease functional reserve [5,6]. The
effectiveness of the cough generated by such muscles has not
been studied to the authors’ knowledge. This has generated
some difﬁculties such as lack of reference to studies in relation
to similar themes or methodologies on the CPF values.
The consequence of inspiratory muscle weakness is the loss
of ability to perform a deep inspiration, which is necessary to
maintain peripheral alveolar ventilation in addition to affect-
ing the ﬁrst phase of cough (deep breath). The weakness of
the expiratory muscles may be seen in a reduction in maximal
expiratory pressure and reduced ability to perform a deep
expiration and cough [15].
The CPF as a functional marker in COPD would therefore
appear to address both inspiratory and expiratory muscle
strength with an advantage of giving us an idea about cough
strength.One of the limitations of the voluntary evaluation of CPF is
the understanding and cooperation of the subjects. Also, the
cough reﬂex mechanism would be triggered in a reasonable
way to the method of evaluation. The differences in voluntary
and reﬂex cough go beyond the way they are triggered. During
the voluntary cough the expiratory and accessory muscle
action only generates one CPF. On the other hand, during
the reﬂex cough the muscle action is harmonious and simulta-
neous, generating two or more peak expiratory ﬂows of lower
amplitude [16].
Cough peak ﬂow can therefore be used as a cheap assess-
ment tool for patients with severe COPD to identify their risk
of developing frequent exacerbation which increases the bur-
den of the disease and impacts on morbidity and mortality.
Further clinical studies need to be designed to determine
which threshold levels of CPF result in increased morbidity
for COPD patients with respiratory muscle weakness. These
could act as a reference against which measurements from
patients with respiratory muscle weakness could be compared
in order to identify early those at risk of problems with cough
and secretion clearance. This information could be used in
developing prevention programs by identifying and interven-
ing in patients at risk. Expiratory muscles can be speciﬁcally
trained and targeted in pulmonary rehabilitation programs
with improvement of both strength and endurance in patients
with COPD. This improvement is associated with an increase
in exercise performance and no signiﬁcant change in the
sensation of dyspnea in daily activities [17].
Cough peak ﬂow is a bedside cheap test that can guide
respiratory physicians in tailoring their treatment of advanced
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